title: Efficacy and safety of propranolol for epistaxis in hereditary haemorrhagic telangiectasia: retrospective, then prospective study, in a total of 21 patients.
authors.affiliation: Service de médecine interne et immunologie clinique, Hôpital Saint André, Bordeaux, France.
authors.forename: A
authors.initials: A
authors.lastname: Contis
authors.affiliation: Service de médecine interne et immunologie clinique, Hôpital Saint André, Bordeaux, France.
authors.forename: N
authors.initials: N
authors.lastname: Gensous
authors.affiliation: Service de médecine interne, Hôpital Haut- Lévêque, Pessac, France.
authors.forename: J F
authors.initials: JF
authors.lastname: Viallard
authors.affiliation: Service de génétique médicale, Hôpital Pellegrin, Bordeaux, France.
authors.forename: C
authors.initials: C
authors.lastname: Goizet
authors.affiliation: Service de dermatologie pédiatrique et Centre de référence maladies rares de la peau, Hôpital Pellegrin, Bordeaux, France.
authors.forename: C
authors.initials: C
authors.lastname: Léauté-Labrèze
authors.affiliation: Service de médecine interne et immunologie clinique, Hôpital Saint André, Bordeaux, France.
authors.forename: P
authors.initials: P
authors.lastname: Duffau
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D004844:Epistaxis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000627:therapeutic use*; D011446:Prospective Studies; D012189:Retrospective Studies; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000150:complications*; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D011433:Propranolol